Vitamin D and the Health of Blood Vessels in Kidney Disease
Chronic Kidney Disease (CKD)
About this trial
This is an interventional treatment trial for Chronic Kidney Disease (CKD) focused on measuring Vitamin D, pulse wave velocity
Eligibility Criteria
Inclusion Criteria:
- patients with an estimated glomerular filtration rate (eGFR) between 15 - 45 ml/min, and <2ml/min change in glomerular filtration rate (GFR) over the past 6 months
- treated with maximal conventional cardiovascular disease (CVD) risk reduction medications
Exclusion Criteria:
- patients with estimated glomerular filtration rate (eGFR) change of >2.1 ml/min over the past 6 months
- those who have terminal malignancies
- those with planned transplant within 6 months, or who are likely to commence renal replacement therapy (dialysis) within the 6 months after enrolment
- those with active infections or active inflammatory diseases (Systemic Lupus Erythematosus (SLE), vasculitis)
- those who refuse to give informed consent
Sites / Locations
- St Paul's Hospital & Vancouver General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
1.
2.
3.
1,25 Vitamin D (0.50ug *3 per week) This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health
25 Vitamin D (5000IU * 3 per week) This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health
Placebo given orally 3xweek for six months